Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 44

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 44
---

2025 Form 10-Q | 23

Three months endedMarch 31,(in millions)20252024OncologyImbruvicaUnited States$529 $610 Collaboration revenues209 228 Total$738 $838 VenclextaUnited States$312 $281 International353 333 Total$665 $614 ElahereUnited States$165 $64 International14 — Total$179 $64 EpkinlyCollaboration revenues$36 $22 International15 5 Total$51 $27 AestheticsBotox CosmeticUnited States$295 $389 International261 244 Total$556 $633 Juvederm CollectionUnited States$75 $106 International156 191 Total$231 $297 Other AestheticsUnited States$270 $281 International45 38 Total$315 $319 Eye CareOzurdexUnited States$30 $34 International93 97 Total$123 $131 Lumigan/GanfortUnited States$48 $29 International58 62 Total$106 $91 Alphagan/CombiganUnited States$26 $15 International34 44 Total$60 $59 Other Eye CareUnited States$117 $149 International100 108 Total$217 $257 Other Key ProductsMavyretUnited States$142 $144 International164 205 Total$306 $349 CreonUnited States$355 $285 Linzess/ConstellaUnited States$139 $257 International9 9 Total$148 $266 All other$747 $744 Total net revenues$13,343 $12,310 

See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7). 

2025 Form 10-Q | 24

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of the financial condition